Atheromatosis - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Atheromatosis

The Experts below are selected from a list of 234 Experts worldwide ranked by ideXlab platform

Jose M Valdivielso – 1st expert on this subject based on the ideXlab platform

  • association of the rs495392 klotho polymorphism with Atheromatosis progression in patients with chronic kidney disease
    Nephrology Dialysis Transplantation, 2019
    Co-Authors: Jose M Valdivielso, Elvira Fernandez, Milica Bozic, Rajesh Kumar Galimudi, Marcelino Bermudezlopez, Juan F Navarrogonzalez, Angels Betriu

    Abstract:

    Background Prevalence of atherosclerotic cardiovascular disease and its rate of progression are higher in patients with chronic kidney disease (CKD) compared with the general population. Mineral metabolism parameters have been shown to be involved in the increased velocity of Atheromatosis progression. The aim of this study is to determine the role of 11 single-nucleotide polymorphisms (SNPs) of the Klotho gene on the rate of atherosclerosis progression in CKD. Methods This was a multicentre, prospective, observational study of 1439 CKD patients from the NEFRONA cohort. Carotid and femoral ultrasounds were performed at baseline and after 24 months in 10 arterial territories. Progression of Atheromatosis was defined as an increase in the number of territories with plaque. Genotyping of 11 SNPs of the Klotho gene was performed and its association with Atheromatosis progression was determined by multivariate logistic regression. Results Bivariate analysis showed that none of the 11 SNPs was associated with atheroma plaque prevalence, but 3 of them (rs495392, rs562020 and rs567170) showed association with Atheromatosis progression. The multivariate analysis revealed that only rs495392 showed a statistically significant association with Atheromatosis progression, after adjustment for several parameters known to affect it in CKD patients. Thus, the presence of one allele T was associated with a reduction of 30% of the odds of progression, whereas the presence of the two T alleles was associated with a decrease close to 50%. Conclusions The presence of the allele T of the SNP rs495392 of the Klotho gene is associated with a decrease in the odds of progression of Atheromatosis in CKD patients.

  • relationship between low levels of circulating trail and Atheromatosis progression in patients with chronic kidney disease
    PLOS ONE, 2018
    Co-Authors: Maria Vittoria Arcidiacono, Jose M Valdivielso, Angels Betriu, Elvira Fernandez, Erika Rimondi, Elisa Maietti, Elisabetta Melloni, Veronica Tisato, Stefania Gallo, Rebecca Voltan

    Abstract:

    Background
    Chronic kidney disease (CKD) patients experience a high risk of cardiovascular disease (CV); however, the factors involved in CV-related morbidity and mortality in these patients have not been fully defined. Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) is a cytokine, which exhibits pleiotropic activities on endothelial, vascular smooth muscle and inflammatory cells, with relevant effects on atheromatous plaque formation. On this basis, the present study aims to investigate the role of TRAIL in Atheromatosis progression in CKD patients.

    Methods
    Circulating TRAIL levels were measured in 378 CKD patients belonging to the Spanish National Observatory of Atherosclerosis in Nephrology (NEFRONA) study. All patients were free of previous CV events. Carotid and femoral B-mode ultrasound was performed to detect the presence of plaque at baseline and after 24 months of follow-up.

    Results
    The lowest levels of TRAIL at baseline were significantly (p<0.05) associated with the appearance, after 24 months of follow-up, of at least two new atheromatous plaques in all territories and of one new plaque in the carotid artery, even after adjusting for CV risk factors. In addition, the patients with low levels of TRAIL at baseline were characterized by the presence of at least one hypoechoic plaque in the carotid artery. This association was significant (p<0.05) even after adjusting for CKD stage. Conclusions Overall, the results of our study suggest TRAIL as an assertable independent prognostic biomarker for Atheromatosis plaque formation in CKD patients. This observation further supports the potential role of TRAIL for the prevention/treatment of CV disease.

  • Relationship between low levels of circulating TRAIL and Atheromatosis progression in patients with chronic kidney disease.
    PLOS ONE, 2018
    Co-Authors: Maria Vittoria Arcidiacono, Jose M Valdivielso, Angels Betriu, Elvira Fernandez, Erika Rimondi, Elisa Maietti, Elisabetta Melloni, Veronica Tisato, Stefania Gallo, Rebecca Voltan

    Abstract:

    Background
    Chronic kidney disease (CKD) patients experience a high risk of cardiovascular disease (CV); however, the factors involved in CV-related morbidity and mortality in these patients have not been fully defined. Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) is a cytokine, which exhibits pleiotropic activities on endothelial, vascular smooth muscle and inflammatory cells, with relevant effects on atheromatous plaque formation. On this basis, the present study aims to investigate the role of TRAIL in Atheromatosis progression in CKD patients.

    Methods
    Circulating TRAIL levels were measured in 378 CKD patients belonging to the Spanish National Observatory of Atherosclerosis in Nephrology (NEFRONA) study. All patients were free of previous CV events. Carotid and femoral B-mode ultrasound was performed to detect the presence of plaque at baseline and after 24 months of follow-up.

    Results
    The lowest levels of TRAIL at baseline were significantly (p

Elvira Fernandez – 2nd expert on this subject based on the ideXlab platform

  • association of the rs495392 klotho polymorphism with Atheromatosis progression in patients with chronic kidney disease
    Nephrology Dialysis Transplantation, 2019
    Co-Authors: Jose M Valdivielso, Elvira Fernandez, Milica Bozic, Rajesh Kumar Galimudi, Marcelino Bermudezlopez, Juan F Navarrogonzalez, Angels Betriu

    Abstract:

    Background Prevalence of atherosclerotic cardiovascular disease and its rate of progression are higher in patients with chronic kidney disease (CKD) compared with the general population. Mineral metabolism parameters have been shown to be involved in the increased velocity of Atheromatosis progression. The aim of this study is to determine the role of 11 single-nucleotide polymorphisms (SNPs) of the Klotho gene on the rate of atherosclerosis progression in CKD. Methods This was a multicentre, prospective, observational study of 1439 CKD patients from the NEFRONA cohort. Carotid and femoral ultrasounds were performed at baseline and after 24 months in 10 arterial territories. Progression of Atheromatosis was defined as an increase in the number of territories with plaque. Genotyping of 11 SNPs of the Klotho gene was performed and its association with Atheromatosis progression was determined by multivariate logistic regression. Results Bivariate analysis showed that none of the 11 SNPs was associated with atheroma plaque prevalence, but 3 of them (rs495392, rs562020 and rs567170) showed association with Atheromatosis progression. The multivariate analysis revealed that only rs495392 showed a statistically significant association with Atheromatosis progression, after adjustment for several parameters known to affect it in CKD patients. Thus, the presence of one allele T was associated with a reduction of 30% of the odds of progression, whereas the presence of the two T alleles was associated with a decrease close to 50%. Conclusions The presence of the allele T of the SNP rs495392 of the Klotho gene is associated with a decrease in the odds of progression of Atheromatosis in CKD patients.

  • relationship between low levels of circulating trail and Atheromatosis progression in patients with chronic kidney disease
    PLOS ONE, 2018
    Co-Authors: Maria Vittoria Arcidiacono, Jose M Valdivielso, Angels Betriu, Elvira Fernandez, Erika Rimondi, Elisa Maietti, Elisabetta Melloni, Veronica Tisato, Stefania Gallo, Rebecca Voltan

    Abstract:

    Background
    Chronic kidney disease (CKD) patients experience a high risk of cardiovascular disease (CV); however, the factors involved in CV-related morbidity and mortality in these patients have not been fully defined. Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) is a cytokine, which exhibits pleiotropic activities on endothelial, vascular smooth muscle and inflammatory cells, with relevant effects on atheromatous plaque formation. On this basis, the present study aims to investigate the role of TRAIL in Atheromatosis progression in CKD patients.

    Methods
    Circulating TRAIL levels were measured in 378 CKD patients belonging to the Spanish National Observatory of Atherosclerosis in Nephrology (NEFRONA) study. All patients were free of previous CV events. Carotid and femoral B-mode ultrasound was performed to detect the presence of plaque at baseline and after 24 months of follow-up.

    Results
    The lowest levels of TRAIL at baseline were significantly (p<0.05) associated with the appearance, after 24 months of follow-up, of at least two new atheromatous plaques in all territories and of one new plaque in the carotid artery, even after adjusting for CV risk factors. In addition, the patients with low levels of TRAIL at baseline were characterized by the presence of at least one hypoechoic plaque in the carotid artery. This association was significant (p<0.05) even after adjusting for CKD stage. Conclusions Overall, the results of our study suggest TRAIL as an assertable independent prognostic biomarker for Atheromatosis plaque formation in CKD patients. This observation further supports the potential role of TRAIL for the prevention/treatment of CV disease.

  • Relationship between low levels of circulating TRAIL and Atheromatosis progression in patients with chronic kidney disease.
    PLOS ONE, 2018
    Co-Authors: Maria Vittoria Arcidiacono, Jose M Valdivielso, Angels Betriu, Elvira Fernandez, Erika Rimondi, Elisa Maietti, Elisabetta Melloni, Veronica Tisato, Stefania Gallo, Rebecca Voltan

    Abstract:

    Background
    Chronic kidney disease (CKD) patients experience a high risk of cardiovascular disease (CV); however, the factors involved in CV-related morbidity and mortality in these patients have not been fully defined. Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) is a cytokine, which exhibits pleiotropic activities on endothelial, vascular smooth muscle and inflammatory cells, with relevant effects on atheromatous plaque formation. On this basis, the present study aims to investigate the role of TRAIL in Atheromatosis progression in CKD patients.

    Methods
    Circulating TRAIL levels were measured in 378 CKD patients belonging to the Spanish National Observatory of Atherosclerosis in Nephrology (NEFRONA) study. All patients were free of previous CV events. Carotid and femoral B-mode ultrasound was performed to detect the presence of plaque at baseline and after 24 months of follow-up.

    Results
    The lowest levels of TRAIL at baseline were significantly (p

Angels Betriu – 3rd expert on this subject based on the ideXlab platform

  • are obesity indices useful for detecting subclinical Atheromatosis in a middle aged population
    Obesity Facts, 2020
    Co-Authors: Enric Sanchez, Angels Betriu, Marta Sanchez, Ferran Rius, Gerard Torres, Francesc Purroy, Reinald Pamplona, Marta Ortega, Carolina Lopezcano, Marta Hernandez

    Abstract:

    OBJECTIVE There is a close relationship between excess adiposity and cardiovascular disease. Although body mass index (BMI) is the most used approach to estimate excess weight, other anthropometric indices have been developed to measure total body and abdominal adiposity. Here, our objective was to assess the usefulness of these anthropometric indices to detect subclinical atheromatous disease. METHODS A cross-sectional study with 6,809 middle-aged subjects (mean age, 57 [53-63] years) with low to moderate cardiovascular risk from the ILERVAS project. Measures of total body fat (BMI, Clinica Universidad de Navarra – Body Adiposity Estimator [CUN-BAE], and Deurenberg’s formula) and central adiposity (waist and neck circumferences, conicity index, waist-to-height ratio, Bonora’s equation, the A body adiposity index, and body roundness index) were performed in all participants. Bilateral carotid and femoral ultrasound vascular studies allowed the identification of subjects with plaque. -Results: All measured indices were significantly higher in males with subclinical carotid or femoral plaques (p ≤ 0.021 for all). Also, a positive and significant correlation between all indices and the number of affected territories was found (p ≤ 0.013 for all). From the ROC analysis, all measurements identified patients with asymptomatic Atheromatosis but none of them helped make clinical decisions. Regarding females, the results were less conclusive. CONCLUSION Obesity indices are related to subclinical Atheromatosis, especially in men, in a large cohort of middle-aged subjects. However, the indices could not detect the presence of arterial plaque, so, when used in isolation, are unlikely to be decisive.

  • association of the rs495392 klotho polymorphism with Atheromatosis progression in patients with chronic kidney disease
    Nephrology Dialysis Transplantation, 2019
    Co-Authors: Jose M Valdivielso, Elvira Fernandez, Milica Bozic, Rajesh Kumar Galimudi, Marcelino Bermudezlopez, Juan F Navarrogonzalez, Angels Betriu

    Abstract:

    Background Prevalence of atherosclerotic cardiovascular disease and its rate of progression are higher in patients with chronic kidney disease (CKD) compared with the general population. Mineral metabolism parameters have been shown to be involved in the increased velocity of Atheromatosis progression. The aim of this study is to determine the role of 11 single-nucleotide polymorphisms (SNPs) of the Klotho gene on the rate of atherosclerosis progression in CKD. Methods This was a multicentre, prospective, observational study of 1439 CKD patients from the NEFRONA cohort. Carotid and femoral ultrasounds were performed at baseline and after 24 months in 10 arterial territories. Progression of Atheromatosis was defined as an increase in the number of territories with plaque. Genotyping of 11 SNPs of the Klotho gene was performed and its association with Atheromatosis progression was determined by multivariate logistic regression. Results Bivariate analysis showed that none of the 11 SNPs was associated with atheroma plaque prevalence, but 3 of them (rs495392, rs562020 and rs567170) showed association with Atheromatosis progression. The multivariate analysis revealed that only rs495392 showed a statistically significant association with Atheromatosis progression, after adjustment for several parameters known to affect it in CKD patients. Thus, the presence of one allele T was associated with a reduction of 30% of the odds of progression, whereas the presence of the two T alleles was associated with a decrease close to 50%. Conclusions The presence of the allele T of the SNP rs495392 of the Klotho gene is associated with a decrease in the odds of progression of Atheromatosis in CKD patients.

  • relationship between low levels of circulating trail and Atheromatosis progression in patients with chronic kidney disease
    PLOS ONE, 2018
    Co-Authors: Maria Vittoria Arcidiacono, Jose M Valdivielso, Angels Betriu, Elvira Fernandez, Erika Rimondi, Elisa Maietti, Elisabetta Melloni, Veronica Tisato, Stefania Gallo, Rebecca Voltan

    Abstract:

    Background
    Chronic kidney disease (CKD) patients experience a high risk of cardiovascular disease (CV); however, the factors involved in CV-related morbidity and mortality in these patients have not been fully defined. Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) is a cytokine, which exhibits pleiotropic activities on endothelial, vascular smooth muscle and inflammatory cells, with relevant effects on atheromatous plaque formation. On this basis, the present study aims to investigate the role of TRAIL in Atheromatosis progression in CKD patients.

    Methods
    Circulating TRAIL levels were measured in 378 CKD patients belonging to the Spanish National Observatory of Atherosclerosis in Nephrology (NEFRONA) study. All patients were free of previous CV events. Carotid and femoral B-mode ultrasound was performed to detect the presence of plaque at baseline and after 24 months of follow-up.

    Results
    The lowest levels of TRAIL at baseline were significantly (p<0.05) associated with the appearance, after 24 months of follow-up, of at least two new atheromatous plaques in all territories and of one new plaque in the carotid artery, even after adjusting for CV risk factors. In addition, the patients with low levels of TRAIL at baseline were characterized by the presence of at least one hypoechoic plaque in the carotid artery. This association was significant (p<0.05) even after adjusting for CKD stage. Conclusions Overall, the results of our study suggest TRAIL as an assertable independent prognostic biomarker for Atheromatosis plaque formation in CKD patients. This observation further supports the potential role of TRAIL for the prevention/treatment of CV disease.